about
Guidelines for the use and interpretation of assays for monitoring autophagyHOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemiaAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroEradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinibIsolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.Characterization of cancer stem cells in chronic myeloid leukaemia.Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.Predictive response-relevant clustering of expression data provides insights into disease processes.Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaBortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cellsEffective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.Investigation into omacetaxine solution stability for in vitro study.JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateExpression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cellsEvolution of bone marrow transplantation--the original immunotherapy.Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny.Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsSecond-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinibChronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survivalA consensus on fungal polymerase chain reaction diagnosis?: a United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections.Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemiaPunish the parent not the progeny.Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.Can we afford to let sleeping dogs lie?Evolving molecular therapy for chronic myeloid leukaemia--are we on target?Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
P50
Q21996341-1103C0B8-BFD9-464C-A47A-22CDA90EB6CAQ28253572-FBB84FD6-C090-40DE-A6FC-5CB35789CFF6Q28477903-7C74ED91-3872-464D-B630-0B9F668176C2Q30873646-3477AFA6-9733-44B1-9778-E0A5DD40C024Q33178852-A555F85C-150B-42B7-A575-4D2EE642389BQ33303597-A78A61EA-8846-4DB1-BB10-8FC6274EFC09Q33368010-5E55EC85-A4C6-457E-8205-E8CA1CAE6A4FQ33518153-F95A8B6E-B9D2-414D-BC90-BFB0FCE3A864Q33613465-ED7C9F42-DA5D-4CD0-9682-93309462145EQ33632220-272C593F-A705-4715-BE7A-C939B644D00FQ33747277-49250E76-DF2E-434A-A3AB-D2289400F888Q33806036-0F2359BB-688F-47AD-96F7-B8A4F48EE0B9Q33866597-F6C68C8F-AAC7-41C9-96EE-CB3B02B5D881Q33989052-07CC6C06-FCF8-46C2-88E2-763C453F08E4Q34106870-C0588495-D821-4996-A3D3-13C232E4CF1DQ34117463-BB5F063A-CC6B-4BF9-98D1-A867EB8B74C9Q34184723-8CBB1F2A-9D72-4AA2-B4CF-53A65B02E6C0Q34203955-F449B62D-523B-464B-BED0-67741B68F759Q34207573-115E07B4-2F76-4E88-BCE0-B1B1ADFFC9F7Q34284760-758940C9-4C0A-4D86-9F3F-032D1D64405DQ34383220-F58891D0-D979-4D87-A40B-3F5904486F99Q34540132-9F6F2AEE-62BD-46C7-96E9-A7C82D0AB127Q34605266-33092BCB-B401-49E7-B3EE-C0FC0BED853FQ34750582-BE119501-F6D3-4EE3-BA20-5B8CE0DFB1CCQ34806728-311736BC-1618-45AD-ACB6-11A8DB1E6D11Q35596901-34718013-E989-41F8-8F96-19B2859AA573Q35774432-72D0B2C0-577D-42A0-93D3-9AF4B92E0849Q35776432-2282554C-EEE2-4C21-99F8-48143B9434D7Q35790217-69550131-EE9C-403F-9540-6213C5B76C7DQ35903505-67AFBEC6-888E-49D2-9863-2F702E736B90Q35940421-451F8306-AD7E-4BDF-A26E-A7BEF59D186DQ35986641-D11405FB-7C6D-4ECD-BBD3-A5CEA14BF0BDQ36010487-0FCF94C0-5E75-45A7-8D9A-63AC2708D7ACQ36030919-4E6FD8AE-C5F2-4EF8-A5E8-309CA4A81DCFQ36061748-66DCE2B2-C6DA-40A6-A7BD-6141BFEA09F3Q36276288-1A91E2E1-7944-480B-A682-24D429E3A8FCQ36445910-A6407CF4-8655-4E64-877F-003D11F358B2Q36557199-3AC20D4D-3F65-4AB1-A937-09592481BC83Q36666798-3104CD7B-913E-409E-963D-4247AC04968DQ36697774-2712A43D-7956-4D06-B05F-0C06DF3F8625
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tessa L Holyoake
@ast
Tessa L Holyoake
@en
Tessa L Holyoake
@es
Tessa L Holyoake
@nl
type
label
Tessa L Holyoake
@ast
Tessa L Holyoake
@en
Tessa L Holyoake
@es
Tessa L Holyoake
@nl
altLabel
tessa holyoake
@en
prefLabel
Tessa L Holyoake
@ast
Tessa L Holyoake
@en
Tessa L Holyoake
@es
Tessa L Holyoake
@nl
P1053
M-3668-2015
P106
P21
P31
P496
0000-0002-0608-6066